GB201022077D0 - Inactivated poliovaccine - Google Patents

Inactivated poliovaccine

Info

Publication number
GB201022077D0
GB201022077D0 GBGB1022077.0A GB201022077A GB201022077D0 GB 201022077 D0 GB201022077 D0 GB 201022077D0 GB 201022077 A GB201022077 A GB 201022077A GB 201022077 D0 GB201022077 D0 GB 201022077D0
Authority
GB
United Kingdom
Prior art keywords
sabin
coding region
base pairs
inactivated poliovaccine
poliovaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1022077.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Public Health England
Original Assignee
Health Protection Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Protection Agency filed Critical Health Protection Agency
Priority to GBGB1022077.0A priority Critical patent/GB201022077D0/en
Publication of GB201022077D0 publication Critical patent/GB201022077D0/en
Priority to AU2011350995A priority patent/AU2011350995B2/en
Priority to EP11807966.4A priority patent/EP2658571B1/en
Priority to US13/977,399 priority patent/US9402892B2/en
Priority to ES11807966.4T priority patent/ES2574178T3/es
Priority to JP2013546763A priority patent/JP5955860B2/ja
Priority to CA2821859A priority patent/CA2821859C/en
Priority to BR112013017014-0A priority patent/BR112013017014B1/pt
Priority to CN201180063532.4A priority patent/CN103391788B/zh
Priority to DK11807966.4T priority patent/DK2658571T3/en
Priority to RU2013135290/10A priority patent/RU2599453C2/ru
Priority to PCT/GB2011/001779 priority patent/WO2012090000A1/en
Priority to ZA2013/04415A priority patent/ZA201304415B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32661—Methods of inactivation or attenuation
    • C12N2770/32662—Methods of inactivation or attenuation by genetic engineering
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
GBGB1022077.0A 2010-12-29 2010-12-29 Inactivated poliovaccine Ceased GB201022077D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB1022077.0A GB201022077D0 (en) 2010-12-29 2010-12-29 Inactivated poliovaccine
PCT/GB2011/001779 WO2012090000A1 (en) 2010-12-29 2011-12-29 Inactivated poliovaccine
CA2821859A CA2821859C (en) 2010-12-29 2011-12-29 Inactivated poliovaccine
EP11807966.4A EP2658571B1 (en) 2010-12-29 2011-12-29 Inactivated poliovaccine
US13/977,399 US9402892B2 (en) 2010-12-29 2011-12-29 Inactivated poliovaccine
ES11807966.4T ES2574178T3 (es) 2010-12-29 2011-12-29 Vacuna inactivada contra la poliomielitis
JP2013546763A JP5955860B2 (ja) 2010-12-29 2011-12-29 不活化ポリオワクチン
AU2011350995A AU2011350995B2 (en) 2010-12-29 2011-12-29 Inactivated poliovaccine
BR112013017014-0A BR112013017014B1 (pt) 2010-12-29 2011-12-29 Poliovírus recombinante atenuado, seu uso, vacina e método para a preparação de uma poliovacina inativada
CN201180063532.4A CN103391788B (zh) 2010-12-29 2011-12-29 灭活的脊髓灰质炎疫苗
DK11807966.4T DK2658571T3 (en) 2010-12-29 2011-12-29 Inactivated polio vaccine
RU2013135290/10A RU2599453C2 (ru) 2010-12-29 2011-12-29 Инактивированная полиовакцина
ZA2013/04415A ZA201304415B (en) 2010-12-29 2013-06-14 Inactivated poliovaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1022077.0A GB201022077D0 (en) 2010-12-29 2010-12-29 Inactivated poliovaccine

Publications (1)

Publication Number Publication Date
GB201022077D0 true GB201022077D0 (en) 2011-02-02

Family

ID=43599090

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1022077.0A Ceased GB201022077D0 (en) 2010-12-29 2010-12-29 Inactivated poliovaccine

Country Status (13)

Country Link
US (1) US9402892B2 (enExample)
EP (1) EP2658571B1 (enExample)
JP (1) JP5955860B2 (enExample)
CN (1) CN103391788B (enExample)
AU (1) AU2011350995B2 (enExample)
BR (1) BR112013017014B1 (enExample)
CA (1) CA2821859C (enExample)
DK (1) DK2658571T3 (enExample)
ES (1) ES2574178T3 (enExample)
GB (1) GB201022077D0 (enExample)
RU (1) RU2599453C2 (enExample)
WO (1) WO2012090000A1 (enExample)
ZA (1) ZA201304415B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0615933D0 (en) 2006-08-10 2006-09-20 Nat Inst Biological Standards & Control Attenuated polioviruses
SG10201810846WA (en) * 2014-06-17 2019-01-30 Janssen Vaccines & Prevention Bv Cold-adapted-viral-attenuation (cava) and novel attenuated poliovirus strains
GB201700825D0 (en) * 2017-01-17 2017-03-01 Sec Dep For Health Poliovaccine
CN119055763A (zh) * 2018-03-30 2024-12-03 生物模仿公司 辐照灭活的脊髓灰质炎病毒、包含其的组合物及制备方法
WO2020075197A1 (en) * 2018-10-10 2020-04-16 Biological E Limited Inactivated poliomyelitis vaccine composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8901094D0 (en) 1989-01-18 1989-03-15 Almond Jeffrey W Attenuated viruses
RU2215035C2 (ru) * 1991-12-06 2003-10-27 Уайтхэд институт фор биомедикл рисерч Рекомбинантный полиовирусный вектор (варианты), способ его получения (варианты), способ индукции иммунного ответа у индивидуума (варианты), способ получения белка (варианты), вакцинная композиция для терапии или профилактики инфекционных заболеваний (варианты)
GB9705669D0 (en) 1997-03-19 1997-05-07 British Tech Group Attenuated polioviruses
GB9817082D0 (en) 1998-08-06 1998-10-07 Btg Int Ltd Attenuated poliovirus vaccine
GB0615933D0 (en) * 2006-08-10 2006-09-20 Nat Inst Biological Standards & Control Attenuated polioviruses

Also Published As

Publication number Publication date
WO2012090000A1 (en) 2012-07-05
CA2821859A1 (en) 2012-07-05
BR112013017014B1 (pt) 2020-12-15
CN103391788A (zh) 2013-11-13
JP5955860B2 (ja) 2016-07-20
AU2011350995B2 (en) 2016-11-24
ES2574178T3 (es) 2016-06-15
RU2599453C2 (ru) 2016-10-10
US20130344108A1 (en) 2013-12-26
ZA201304415B (en) 2014-03-26
AU2011350995A8 (en) 2013-07-18
EP2658571B1 (en) 2016-03-02
CN103391788B (zh) 2016-04-20
DK2658571T3 (en) 2016-05-17
US9402892B2 (en) 2016-08-02
JP2014502508A (ja) 2014-02-03
RU2013135290A (ru) 2015-02-10
CA2821859C (en) 2020-07-07
AU2011350995A1 (en) 2013-07-04
EP2658571A1 (en) 2013-11-06
BR112013017014A2 (pt) 2016-10-25

Similar Documents

Publication Publication Date Title
MY151062A (en) Pseudoinfectious flavivirus and uses thereof
MX2016016722A (es) Coronavirus.
AU2011350995A8 (en) Inactivated poliovaccine
SG10201407640PA (en) Hepatitis b virus specific antibody and uses thereof
EA200900288A1 (ru) Вакцина
WO2005042728A3 (en) Immortalized avian cell lines for virus production
EP3372685A3 (en) Cell lines for virus production and methods of use
GB2438802A (en) Structure of the hepatitis C virus NS5A protein
SG170751A1 (en) Extractions and methods comprising elder species
NZ607477A (en) Non-natural amino acid replication-dependent microorganisms and vaccines
WO2006074346A3 (en) RNAi MODULATION OF RSV AND THERAPEUTIC USES THEREOF
MX2019005401A (es) Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma.
MX2013004159A (es) Proteina vp6 de la capside de norovirus y de rotavirus para el uso como vacuna combinada.
MX2010005701A (es) Metodo para producir cepa viral vacunal de un virus de la familia reoviridae.
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
WO2008017870A8 (en) Attenuated polio viruses
MX2007009628A (es) Virus de acido ribonucleico en replicacion como vacunas.
PH12017550047B1 (en) Use of taurine in prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus
MX2021011059A (es) Particulas tipo norovirus con estabilidad mejorada.
Tahat et al. Soft topological rings
WO2006078648A3 (en) Rhinovirus vaccines
WO2007044483A3 (en) Attenuated vaccines for non-segmented negative sense rna viruses
PH12014501824A1 (en) Creamer composition comprising protein and hydroxypropyl starch
PH12020551944A1 (en) Reverse peptide vaccine
PH12018502320A1 (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)